Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol‐Associated Cirrhosis
In this large real-world study, baclofen was associated with a higher risk of hepatic encephalopathy compared with acamprosate in patients with compensated alcohol-associated cirrhosis.
Authors
- Walid S. Ayoub (ORCID: https://orcid.org/0000-0002-9123-5918)
- Hirsh D. Trivedi (ORCID: https://orcid.org/0000-0002-8328-9211)
- Aarshi Vipani (ORCID: https://orcid.org/0000-0003-1050-837X)
- Ellen Choi (ORCID: https://orcid.org/0000-0001-9969-5276)
- Y. Wang (ORCID: https://orcid.org/0000-0003-4106-6893)
- Parnian Naji (ORCID: https://orcid.org/0009-0007-5055-3999)
- Sepideh Mehravar
- Hyun‐seok Kim (ORCID: https://orcid.org/0000-0002-0376-0836)
- Yee Hui Yeo
- Julie Yang
- Chun‐Ying Wu
- Alexander Kuo
- Lorenzo Leggio
- Juan Pablo Arab
Institutions
- Cedars-Sinai Medical Center (US)
- National Institute on Drug Abuse (US)
- National Yang Ming Chiao Tung University (TW)
- Virginia Commonwealth University (US)
- University Hospitals of Cleveland (US)
- Englewood Hospital and Medical Center (US)
- National Institute on Alcohol Abuse and Alcoholism (US)
- The University of Texas at Austin (US)
Publication Details
- Journal
- Alimentary Pharmacology & Therapeutics
- Published
- 2026-03-17
- DOI
- https://doi.org/10.1111/apt.70619
- Primary Topic
- Alcohol Consumption and Health Effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00